Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer disease

Sarah M Hartz,Suzanne E. Schindler,Mariss Streitz,Krista Moulder,Jessica M Mozersky,Guoqiao Wang,Chengjie Xiong,John C. Morris
DOI: https://doi.org/10.1101/2024.07.16.24310511
2024-07-22
Abstract:INTRODUCTION: For many patients and caregivers, a major goal of disease-modifying treatments (DMT) for Alzheimer disease (AD) dementia is to extend independence in instrumental and basic activities of daily living (IADLs and BADLs). The goal of this study was to estimate the effect of treatments on the time remaining independent in IADLs and BADLs. METHODS: Participants at the Knight Alzheimer Disease Research Center were selected who were potentially eligible for recent DMT trials: age ≥ 60 years at baseline, clinical diagnosis of very mild or mild AD dementia (global Clinical Dementia Rating (CDR) score 0.5 or 1), biomarker confirmation of amyloid pathology, and at least one follow-up CDR assessment within 5 years. For IADLs, a subset of the Functional Assessment Questionnaire (FAQ) was examined that rated the degree of independence for the following items: paying bills, driving, remembering medications and appointments, and preparing meals. For BADLs, the Personal Care domain of the CDR was used. Mixed-effects logistic and ordinal regression models were used to examine the relationship between CDR Sum Boxes (CDR-SB) and the individual functional outcomes and their components. The change in CDR-SB over time was estimated with linear mixed effects models. RESULTS: 282 participants were followed for an average of 2.9 years (SD 1.3 years). For 50% of individuals, loss of independence occurred at CDR-SB>4.5 for IADLs and at CDR-SB>11.5 for BADLs. For individuals with a baseline CDR-SB=2, treatment would extend independence in IADLs for 10 months (95% CI 4-18 months) for lecanemab and 13 months (95% CI 6-24 months) for the low/medium tau group treated with donanemab. DISCUSSION: Independence in ADLs can be related to CDR-SB and used to demonstrate the effect of AD treatments in extending the time of independent function, a meaningful outcome for patients and their families.
What problem does this paper attempt to address?